# Supplemental digital content

**SUPPLEMENTAL TABLE** **1.** Change from Baseline in Central Corneal Thickness at Each Study Visit in Each Group (Study Eye)

|  |  |
| --- | --- |
|  | **Mean (standard deviation) change from baseline (µm)** |
| **Study 1** | **Omidenepag isopropyl 0.0003% (n=17)** | **Omidenepag isopropyl 0.001% (n=15)** | **Omidenepag isopropyl 0.002% (n=14)** | **Omidenepag isopropyl 0.003% (n=15)** | **Latanoprost 0.005%(n=15)** | **Placebo(n=15)** |
| Week 1 | 7.0 (23.8) | 3.4 (8.2) | 8.4 (9.9) | 7.2 (8.4) | 2.5 (10.8) | 3.7 (10.7) |
| Week 2 | 4.5 (11.0) | 6.8 (11.7) | 6.8 (9.2) | 2.7 (11.3) | –1.2 (9.2) | 2.4 (9.2) |
| Week 4 | 0.2 (6.8) | 2.7 (6.2) | 7.5 (11.9) | 11.9 (11.7) | –1.8 (10.1) | 4.6 (15.1) |
| **Study 2** | **Omidenepag isopropyl 0.0012% (n=32)** | **Omidenepag isopropyl 0.0016% (n=29)** | **Omidenepag isopropyl 0.002% (n=29)** | **Omidenepag isopropyl 0.0025% (n=30)** | **Omidenepag isopropyl 0.003% (n=31)** | **Latanoprost 0.005%****(n=32)** |
| Week 4 | 1.0 (13.2) | 4.7 (12.3) | 7.5 (14.3) | 5.3 (8.7) | 10.9 (13.3) | –1.3 (13.7) |
| Month 2 | 3.3 (20.8) | 3.6 (11.3) | 3.5 (12.4) | 6.8 (12.2) | 11.2 (15.9) | –2.3 (15.9) |
| Month 3 | 3.2 (16.4) | 3.1 (11.2) | 6.8 (13.0) | 5.1 (12.3) | 9.5 (11.4) | –1.4 (13.5) |
| **Study 3** | **Omidenepag isopropyl 0.002% (n=22)** | **Omidenepag isopropyl 0.0025% (n=22)** | **Placebo (n=19)** |
| Week 1 | 24.0 (22.7) | 23.3 (21.3) | 0.6 (18.9) |
| Week 2 | 23.6 (16.3) | 20.4 (17.5) | 4.8 (13.6) |
| Week 4 | 17.7 (13.6) |  16.5 (18.8) | 7.9 (15.4) |